ArticleFrontiers in pharmacology2025
Mitophagy-related gene TRIP13 predicts prognosis and immune response and promotes proliferation and migration
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The incidence of clear cell renal cell carcinoma (ccRCC) is increasing every year. Mitophagy is a unique form of autophagy that plays a crucial role in cancer development and invasion. However, its role in ccRCC remains to be fully elucidated. Methods: After extracting mitophagy-related genes (MRGs), differential expression analysis was performed to screen differentially expressed genes (DEGs). Univariate Cox regression analysis was used to screen prognostic-related DEGs, CNV mutation frequencies were compared, and consensus cluster analysis was constructed to evaluate the survival and functional enrichment status among different subtypes. LASSO Cox regression analysis was used to identify key prognostic genes and construct risk models to evaluate the prognostic value and immune contribution. The protein and mRNA expression levels of independent prognostic genes and their effects on ccRCC function were verified by Results: The study found 174 DEGs, including 9 prognosis-related DEGs. These 9 DEGs were used to cluster ccRCC patients into two subtypes. Significant differences existed between the two subtypes in the survival status and KEGG functions. Finally, three core genes (JUP, TRIP13, and ACAD11) were identified for constructing a risk model, which can accurately predict the prognosis of ccRCC patients and evaluate the immune status. TRIP13 was identified as a key independent prognostic gene for ccRCC, and its protein and mRNA expression levels were highly expressed in ccRCC. ccRCC growth and motility can be markedly inhibited by TRIP13 knockdown, which also increases their susceptibility to destruction by CD8 Conclusion: The prognosis and immune response of patients with ccRCC could be reliably estimated by the model in our cohorts created using MRGs in this research. The development of ccRCC is significantly influenced by MRGs, particularly TRIP13. This study can assist in offering ccRCC patients individualized treatment options.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.